# Development and Validation of the Blood Glucose Measurement Device by Air Analysis Expired

Study · id `cardio:ct-nct05207020` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05207020](<https://clinicaltrials.gov/study/NCT05207020>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05207020

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 130 participants.

## Technical summary

Registry record NCT05207020. Allocation not applicable; no masking; primary purpose diagnostic. Start 2021-12-01 (actual); primary completion 2023-02-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Not applicable
- Enrolled: 130 participants (enrolled count; ClinicalTrials.gov record NCT05207020, source copy `cardio:ctgov-nct05207020-2023-02-13`, retrieved 2026-10-26)
- Started: 2021-12-01 (actual) (ClinicalTrials.gov record NCT05207020, source copy `cardio:ctgov-nct05207020-2023-02-13`, retrieved 2026-10-26)
- Primary completion: 2023-02-09 (actual) (ClinicalTrials.gov record NCT05207020, source copy `cardio:ctgov-nct05207020-2023-02-13`, retrieved 2026-10-26)
- Completion: 2023-02-09 (actual) (ClinicalTrials.gov record NCT05207020, source copy `cardio:ctgov-nct05207020-2023-02-13`, retrieved 2026-10-26)
- Countries: France (ClinicalTrials.gov record NCT05207020, source copy `cardio:ctgov-nct05207020-2023-02-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05207020-2023-02-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Development and Validation of the Blood Glucose Measurement Device by Air Analysis Expired
- Acronym: BOYDSENSE
- Condition: Diabetes Mellitus, Type 2
- Intervention (Device): Glycemia estimated by exhaled air analyzer
- Intervention (Behavioral): Questionnaire
- Intervention (Biological): Veinous glycemia
- Intervention (Biological): Capillary glycemia
- Intervention (Biological): constitution biological collection
- Intervention (Biological): Blood sample
- Intervention (Other): Test meal
- Lead sponsor: University Hospital, Toulouse
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: University Hospital, Toulouse (`cardio:org-university-hospital-toulouse`)

## Provenance

Content hash: a5b26582db1e920ea658ea53ec314262c9a76973778057a220b5a6e8494ae522
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
